Accomplished biopharmaceutical research scientist with experience on clinical stage immuno-oncology and inflammation focused therapeutic programs and a demonstrated track record of cutting-edge research discoveries and high impact contributions. SELECTED ACCOMPLISHMENTSTeam Leader and Key Contributor• Project team leader for APVO436, a bispecific anti-CD123 x anti-CD3 antibody currently being tested in phase I trials for hematological malignancies• Initiated and led the project team in the successful development of Tezepelumab. An effort leading to robust human clinical data published in the New England Journal of Medicine in 2014. Program is currently being tested in global phase 3 trials.• Leader of pre-clinical asthma discovery research efforts charged with developing and communicating strategy for therapeutic target discovery and disease stratification• Extensive experience collaborating with external academic researchers and CROs.Innovation• Excellent record of high impact publications (primary peer-reviewed articles, book chapters, invited reviews) and contributions to Amgen IP• Described novel TSLP biology involving dendritic cells, mast cells, eosinophils, basophils, type 2 innate lymphoid cells and link between TSLP over-expression and atopic dermatitis, asthma and eosinophilic esophagitis• Experienced bench scientist with the ability to contribute to project needs in the laboratory • Involved in cloning and biologic characterization of numerous novel genes and cytokine receptor chainsCommunicator• Extensive experience with project portal presentations, therapeutic area strategy reviews, CEO level overviews, review and presentation of licensing and partnering opportunities• Consistent presentation of abstracts and talks at major external scientific conferences• Developed and delivered AMG 157 project overview presentations to several biopharmaceutical companies around the globeAuthor on 52 Publications and Holder of 8 Patents